Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer | Synapse
June 17, 2003Open Access
Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
These model-based lead-time estimates support a prostate cancer screening interval of more than 1 year.